drugset / Trial / NCT02112214
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
Phase 3
Active not recruiting
5224 enrolled
National Cancer Center, Korea
Chonnam National University Hospital · collabChuncheon Sacred Heart Hospital · collabChung-Ang University Hospital · collabIncheon St.Mary's Hospital/The Catholic University · collabInternational Agency for Research on Cancer · collabKangdong Sacred Heart Hospital · collabKosin University Gospel Hospital · collabKyungpook National University Hospital · collabPusan National University Hospital · collabSMG-SNU Boramae Medical Center · collabUijeongbu St. Mary's Hospital/The Catholic University · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.
Timeline
- Start
- 2014-06
- Primary completion
- 2029-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bismuth Potassium Citrate | Unknown | 300 mg | — |
| Comparator | Lansoprazole | Other / unclassified | 30 mg | — |
| Comparator | Metronidazole | Small molecule | 500 mg | — |
| Comparator | Tetracycline | Unknown | 500 mg | — |